Page last updated: 2024-08-16

sb 202190 and rwj 67657

sb 202190 has been researched along with rwj 67657 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brumlik, MJ; Burow, ME; Curiel, TJ; Daniel, BJ; Khan, IA; Siekierka, J; Wadsworth, S; Wei, S; Zou, W1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1

Other Studies

2 other study(ies) available for sb 202190 and rwj 67657

ArticleYear
Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:12

    Topics: Animals; Antiprotozoal Agents; CD8 Antigens; Dose-Response Relationship, Drug; Drug Design; Drug Synergism; Drug Therapy, Combination; Encephalitozoon cuniculi; Encephalitozoonosis; Enzyme Inhibitors; Female; Humans; Imidazoles; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; p38 Mitogen-Activated Protein Kinases; Pyridines; Time Factors; Toxoplasma; Toxoplasmosis, Animal

2007
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013